Abstract
Nano-engineered particles have been developed to reach specific molecular targets on diseased cells and have been used in various experimental and clinical conditions. The medical application involves diagnostic and therapeutic applications and a large deal of this research concerns malignant disease. Various approaches have been tried to effectively reach the cancer cell and PEGylated liposomes have demonstrated targeting and controlled release of antineoplastic drugs. For cancer diagnostics nanoparticles have been engineered to optimize magnetic resonance imaging, ultrasound imaging and nuclear medicine imaging. Radiolabeled nanoparticles can also be used for therapeutic purposes when tagged with appropriate radionuclides. This article aims to provide an overview how nanomedicine is presently influencing drug design and, more specifically, the development of radiopharmaceuticals for cancer management.
Keywords: Nanoparticles, nanocarriers, oncology, therapy, imaging
Current Radiopharmaceuticals
Title: Nanoparticles in Cancer
Volume: 1 Issue: 1
Author(s): Ernest K.J. Pauwels, Kalevi Kairemo, Paola Erba and Kim Bergstrom
Affiliation:
Keywords: Nanoparticles, nanocarriers, oncology, therapy, imaging
Abstract: Nano-engineered particles have been developed to reach specific molecular targets on diseased cells and have been used in various experimental and clinical conditions. The medical application involves diagnostic and therapeutic applications and a large deal of this research concerns malignant disease. Various approaches have been tried to effectively reach the cancer cell and PEGylated liposomes have demonstrated targeting and controlled release of antineoplastic drugs. For cancer diagnostics nanoparticles have been engineered to optimize magnetic resonance imaging, ultrasound imaging and nuclear medicine imaging. Radiolabeled nanoparticles can also be used for therapeutic purposes when tagged with appropriate radionuclides. This article aims to provide an overview how nanomedicine is presently influencing drug design and, more specifically, the development of radiopharmaceuticals for cancer management.
Export Options
About this article
Cite this article as:
Pauwels K.J. Ernest, Kairemo Kalevi, Erba Paola and Bergstrom Kim, Nanoparticles in Cancer, Current Radiopharmaceuticals 2008; 1 (1) . https://dx.doi.org/10.2174/1874471010801010030
DOI https://dx.doi.org/10.2174/1874471010801010030 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients
Current Drug Targets Recent Advances of MEK Inhibitors and Their Clinical Progress
Current Topics in Medicinal Chemistry Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria
Current Pharmaceutical Design Hibiscus Sabdariffa Linnaeus (Malvaceae), Curcumin and Resveratrol as Alternative Medicinal Agents Against Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology
Central Nervous System Agents in Medicinal Chemistry Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Kisspeptin Mediated Signaling in Cancer
Current Topics in Medicinal Chemistry Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy
Current Molecular Pharmacology Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Harnessing the Power of Cerenkov Luminescence Imaging for Gastroenterology: Cerenkov Luminescence Endoscopy
Current Medical Imaging Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines
Current Medicinal Chemistry The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry